EBR Systems (ASX:EBR), developer of the world's only wireless cardiac pacing device for heart failure, today reported strong commercial and clinical progress for the quarter ended Dec. 31, 2025.
During Q4, the company’s commercial momentum continued, with WiSE System implants doubling from the previous quarter.
A total of 18 commercial patients received the device, bringing the cumulative pilot and limited market release implants to 30.
Nine new purchase agreements were signed, and 11 additional physicians were trained to support broader adoption of the system.
Several implants were performed at leading centers, including the Louis Stokes Cleveland Veterans Affairs Medical Center in Ohio.
On the clinical front, EBR advanced key initiatives. The WiSE-UP post-approval study began, enrolling four patients across multiple sites to evaluate real-world outcomes of left ventricular endocardial pacing in heart failure patients.
The Totally Leadless CRT feasibility study also commenced, with the first patient enrolled at Princess Alexandra Hospital in Brisbane, Australia.
Preliminary unaudited financial results indicate Q4 revenue is expected between US$870,000 and US$935,000, with total 2025 revenue anticipated between US$1.6 million and US$1.6 million, subject to year-end adjustments.
John McCutcheon, EBR Systems’ President & CEO, said, "Q4 2025 demonstrated solid progress across commercial and clinical programs. With continued adoption of the WiSE System and advancement of critical studies, we are building the foundation for broader market access and expanding treatment options for patients with heart failure."